Drug-Induced Long QT Syndrome
Top Cited Papers
- 1 December 2010
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 62 (4) , 760-781
- https://doi.org/10.1124/pr.110.003723
Abstract
The drug-induced long QT syndrome is a distinct clinical entity that has evolved from an electrophysiologic curiosity to a centerpiece in drug regulation and development. This evolution reflects an increasing recognition that a rare adverse drug effect can profoundly upset the balance between benefit and risk that goes into the prescription of a drug by an individual practitioner as well as the approval of a new drug entity by a regulatory agency. This review will outline how defining the central mechanism, block of the cardiac delayed-rectifier potassium current IKr, has contributed to defining risk in patients and in populations. Models for studying risk, and understanding the way in which clinical risk factors modulate cardiac repolarization at the molecular level are discussed. Finally, the role of genetic variants in modulating risk is described.Keywords
This publication has 228 references indexed in Scilit:
- Genome-wide association study identifies eight loci associated with blood pressureNature Genetics, 2009
- Common variants at ten loci modulate the QT interval duration in the QTSCD StudyNature Genetics, 2009
- Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspectiveBritish Journal of Pharmacology, 2008
- Persistent Atrial Fibrillation Is Associated With Reduced Risk of Torsades de Pointes in Patients With Drug-Induced Long QT SyndromeJournal of the American College of Cardiology, 2008
- Relevance of anaesthesia for dofetilide-induced torsades de pointes in α1 -adrenoceptor-stimulated rabbitsBritish Journal of Pharmacology, 2008
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesNature Reviews Drug Discovery, 2007
- Combined pharmacological block of IKr and IKs increases short‐term QT interval variability and provokes torsades de pointesBritish Journal of Pharmacology, 2007
- A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarizationNature Genetics, 2006
- Female gender as a risk factor for torsades de pointes associated with cardiovascular drugsJAMA, 1993
- Torsade de pointes: The long-short initiating sequence and other clinical features: observations in 32 patientsJournal of the American College of Cardiology, 1983